 Connection
David Badesch to Adult
This is a "connection" page, showing publications David Badesch has written about Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.582 |
|
|
|
-
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023 01; 61(1).
Score: 0.040
-
Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019 03; 155(3):565-586.
Score: 0.031
-
Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. Chest. 2018 10; 154(4):848-861.
Score: 0.029
-
Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014 Aug; 146(2):449-475.
Score: 0.022
-
Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9.
Score: 0.018
-
Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Mayo Clin Proc. 2011 Feb; 86(2):105-12.
Score: 0.018
-
Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87.
Score: 0.016
-
Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct; 36(10):2244-9.
Score: 0.016
-
Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 Dec; 34(12):2417-22.
Score: 0.014
-
Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005 Aug 16; 143(4):282-92.
Score: 0.012
-
Preston IR, Badesch D, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Humbert M, McLaughlin VV, Waxman AB, Manimaran S, Mikhailova E, Reddy M, Lau A, de Oliveira Pena J, Souza R. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. 2025 Jul; 66(1).
Score: 0.012
-
Robbins EW, Bradley K, Badesch D, Burger C, Chyboski AM, De Marco T, Hemnes AR, Lammi M, Mathai SC, Melendres-Groves L, Raza F, Sager J, Shlobin O, Thenappan T, Zamanian R, Runo J, Baird GL, Ventetuolo CE. Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR). Ann Am Thorac Soc. 2025 Jun; 22(6):830-837.
Score: 0.012
-
Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M. Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR). Am J Respir Crit Care Med. 2025 Jun; 211(6):1028-1037.
Score: 0.012
-
Hoeper MM, Gomberg-Maitland M, Badesch DB, Gibbs JSR, Grünig E, Kopec G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Manimaran S, Wang X, Miller B, Cornell AG, de Oliveira Pena J, Ghofrani HA, Humbert M. Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. Eur Respir J. 2025 May; 65(5).
Score: 0.012
-
Bailey M, Frantz R, Minhas J, Cascino T, Burger C, Shlobin O, Sager J, Raval A, Lammi M, Runo J, Thenappan T, De Marco T, Ravichandran A, Safdar Z, Lachant D, Badesch D, Yung D, DuBrock H. The Frequency and Predictors of Pulmonary Rehabilitation Referrals Among Patients With Pulmonary Arterial Hypertension: An Analysis of the Pulmonary Hypertension Association Registry. Chest. 2025 Oct; 168(4):996-1006.
Score: 0.012
-
Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Moles VM, Savale L, Vizza CD, Rosenkranz S, Shi Y, Miller B, Mackenzie HS, Kim SS, Loureiro MJ, Patel MJ, Koglin J, Cornell AG, Hoeper MM. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025 May 29; 392(20):1987-2000.
Score: 0.012
-
Hoeper MM, Rosenkranz S, Badesch DB, Humbert M, Langleben D, McConnell JW, Hegab S, Rahner C, Richard JF, Ghofrani HA. Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies. Respir Med. 2025 01; 236:107910.
Score: 0.012
-
Gomberg-Maitland M, Badesch DB, Gibbs JSR, Grünig E, Hoeper MM, Humbert M, Kopec G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Johnson-Levonas AO, Cornell AG, de Oliveira Pena J, Ardeschir Ghofrani H. Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR. J Heart Lung Transplant. 2025 Apr; 44(4):609-624.
Score: 0.012
-
Bull TM, Cool CD, Serls AE, Rai PR, Parr J, Neid JM, Geraci MW, Campbell TB, Voelkel NF, Badesch DB. Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8. Eur Respir J. 2003 Sep; 22(3):403-7.
Score: 0.011
-
McCormick A, Krishnan A, Badesch D, Benza RL, Bull TM, De Marco T, Feldman J, Hemnes AR, Hirsch R, Horn E, Kennedy J, Mathai SC, McConnell W, Pugliese SC, Sager JS, Shlobin OA, Simon MA, Lammi MR. Pulmonary artery compliance in different forms of pulmonary hypertension. Heart. 2023 06 26; 109(14):1098-1105.
Score: 0.010
-
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 04 20; 388(16):1478-1490.
Score: 0.010
-
Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T, Frantz RP, Hemnes A, Mathai SC, Rosenzweig EB, Ryan JJ, Thenappan T. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022 05 03; 11(9):e024969.
Score: 0.010
-
Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, Keyes-Elstein L, D'Aveta C, Spychala M, White RJ, Hassoun PM, Torres F, Sweatt AJ, Molitor JA, Khanna D, Maecker H, Welch B, Goldmuntz E, Nicolls MR. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med. 2021 07 15; 204(2):209-221.
Score: 0.009
-
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 04 01; 384(13):1204-1215.
Score: 0.009
-
Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, Shlobin O, Simon M, Thenappan T, Grinnan D, Ventetuolo C, Al-Naamani N. Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. Am J Respir Crit Care Med. 2021 03 15; 203(6):761-764.
Score: 0.009
-
Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, Zamanian RT. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. Eur Respir J. 2021 02; 57(2).
Score: 0.009
-
Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG. United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. Chest. 2021 01; 159(1):311-327.
Score: 0.009
-
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21; 132(6):425-34.
Score: 0.008
-
Badesch DB, Zamora M, Fullerton D, Weill D, Tuder R, Grover F, Schwarz MI. Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection. J Heart Lung Transplant. 1998 Apr; 17(4):415-22.
Score: 0.007
-
Farber HW, Badesch DB, Benza RL, Elliott CG, Frantz RP, McGoon MD, Selej M, Zhao C, Frost AE. Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. J Heart Lung Transplant. 2018 08; 37(8):948-955.
Score: 0.007
-
McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schüler R, Wiklund I, Peacock A. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016 06 14; 17(1):72.
Score: 0.006
-
Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015 Jul; 46(1):152-64.
Score: 0.006
-
Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, Barst RJ, Rosenberg DM, Miller DP, Hartline BK, Benton WW, Farber HW. Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. Chest. 2015 Feb; 147(2):484-494.
Score: 0.006
-
Gladwin MT, Barst RJ, Gibbs JS, Hildesheim M, Sachdev V, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Berman Rosenzweig E, Badesch DB, Lanzkron S, Castro OL, Taylor JG, Goldsmith JC, Kato GJ, Gordeuk VR, Machado RF. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One. 2014; 9(7):e99489.
Score: 0.006
-
Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, Kato GJ, Ataga KI, Gibbs JS, Castro O, Rosenzweig EB, Sood N, Hsu L, Wilson KC, Telen MJ, Decastro LM, Krishnamurti L, Steinberg MH, Badesch DB, Gladwin MT. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014 Mar 15; 189(6):727-40.
Score: 0.005
-
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 07; 33(7):689-97.
Score: 0.005
-
Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb; 167(2):218-225.e1.
Score: 0.005
-
Badesch DB, Wynne KM, Bonvallet S, Voelkel NF, Ridgway C, Groves BM. Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann Intern Med. 1993 Jul 01; 119(1):44-6.
Score: 0.005
-
Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012 Dec; 142(6):1383-1390.
Score: 0.005
-
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug; 142(2):448-456.
Score: 0.005
-
Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011 Sep 27; 124(13):1452-60.
Score: 0.005
-
Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011 Nov; 140(5):1274-1283.
Score: 0.004
-
Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13; 122(2):164-72.
Score: 0.004
-
Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37.
Score: 0.004
-
Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010 Dec; 138(6):1383-94.
Score: 0.004
-
Jing ZC, Xu XQ, Badesch DB, Jiang X, Wu Y, Liu JM, Wang Y, Pan L, Li HP, Pu JL, Zhang ZL, Yang YJ. Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med. 2009 Aug; 103(8):1136-42.
Score: 0.004
-
Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB, Brown RS, Taichman DB, Trotter J, Zacks S, Horn EM, Kawut SM. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest. 2009 Jun; 135(6):1470-1475.
Score: 0.004
-
Badesch DB, King TE, Schwarz MI. Acute eosinophilic pneumonia: a hypersensitivity phenomenon? Am Rev Respir Dis. 1989 Jan; 139(1):249-52.
Score: 0.004
-
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21; 149(8):521-30.
Score: 0.004
-
McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009 Jan; 135(1):122-129.
Score: 0.004
-
Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008 Oct; 134(4):775-782.
Score: 0.004
-
Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS, Fallon MB. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008 Jul; 48(1):196-203.
Score: 0.004
-
Hemstreet BA, Stolpman N, Badesch DB, May SK, McCollum M. Potassium and phosphorus repletion in hospitalized patients: implications for clinical practice and the potential use of healthcare information technology to improve prescribing and patient safety. Curr Med Res Opin. 2006 Dec; 22(12):2449-55.
Score: 0.003
-
Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006 Sep; 152(3):521-6.
Score: 0.003
-
McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 01; 174(11):1257-63.
Score: 0.003
-
Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006 May 16; 47(10):2049-56.
Score: 0.003
-
Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005 Dec; 26(6):1110-8.
Score: 0.003
-
Fagan KA, Bull TM, Badesch DB, Voelkel NF. Metastatic cancer while receiving continuous prostacyclin therapy. Chest. 2005 Dec; 128(6 Suppl):619S-620S.
Score: 0.003
-
Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 02; 46(3):529-35.
Score: 0.003
-
Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005 Dec; 60(12):1025-30.
Score: 0.003
-
McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005 Feb; 25(2):244-9.
Score: 0.003
-
Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation. 2004 Jun 22; 109(24):2947-52.
Score: 0.003
-
Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul; 124(1):247-54.
Score: 0.003
-
Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun 18; 41(12):2119-25.
Score: 0.003
-
Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, Bristow MR, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst. 2003 Mar; 4(1):27-30.
Score: 0.003
-
McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 Feb; 41(2):293-9.
Score: 0.003
-
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21; 346(12):896-903.
Score: 0.002
-
Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF. Hyperuricemia in severe pulmonary hypertension. Chest. 2000 Jan; 117(1):19-24.
Score: 0.002
-
Frost M, Huffer WE, Sze CI, Badesch D, Cajade-Law AG, Kleinschmidt-DeMasters BK. Cervical spine abnormalities in Down Syndrome. Clin Neuropathol. 1999 Sep-Oct; 18(5):250-9.
Score: 0.002
-
Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999 Jun; 159(6):1925-32.
Score: 0.002
-
Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jöbsis MM, Blackburn SD, Crow JW, Long WA. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997 Mar 18; 95(6):1479-86.
Score: 0.002
-
Beaver TM, Fullerton DA, Zamora MR, Badesch DB, Weill D, Brown JM, Campbell DN, Grover FL. Colon perforation after lung transplantation. Ann Thorac Surg. 1996 Sep; 62(3):839-43.
Score: 0.002
-
Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest. 1996 Sep; 110(3):710-7.
Score: 0.002
-
Gass R, Fisher J, Badesch D, Zamora M, Weinberg A, Melsness H, Grover F, Tully JG, Fang FC. Donor-to-host transmission of Mycoplasma hominis in lung allograft recipients. Clin Infect Dis. 1996 Mar; 22(3):567-8.
Score: 0.002
-
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 01; 334(5):296-301.
Score: 0.002
-
Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994 Feb; 144(2):275-85.
Score: 0.001
-
Truwit JD, Badesch DB, Savage AM, Shelton M. Vibrio vulnificus bacteremia with endocarditis. South Med J. 1987 Nov; 80(11):1457-9.
Score: 0.001
-
Fassler CA, Rodriguez RM, Badesch DB, Stone WJ, Marini JJ. Magnesium toxicity as a cause of hypotension and hypoventilation. Occurrence in patients with normal renal function. Arch Intern Med. 1985 Sep; 145(9):1604-6.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|